Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.
Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H; EXAFIP investigators and the OrphaLung network. Naccache JM, et al. Among authors: chenivesse c. Lancet Respir Med. 2022 Jan;10(1):26-34. doi: 10.1016/S2213-2600(21)00354-4. Epub 2021 Sep 7. Lancet Respir Med. 2022. PMID: 34506761 Clinical Trial.
Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial.
Deslée G, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Thiberville L, Leroy S, Marceau A, Laroumagne S, Mallet JP, Dukic S, Barbe C, Bulsei J, Jolly D, Durand-Zaleski I, Marquette CH; REVOLENS Study Group. Deslée G, et al. JAMA. 2016 Jan 12;315(2):175-84. doi: 10.1001/jama.2015.17821. JAMA. 2016. PMID: 26757466 Free article. Clinical Trial.
Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis.
Rolland-Debord C, Fry S, Giovannelli J, Langlois C, Bricout N, Aguilaniu B, Bellocq A, Le Rouzic O, Dominique S, Delobbe A, François G, Tazi A, Wallaert B, Chenivesse C. Rolland-Debord C, et al. Among authors: chenivesse c. PLoS One. 2017 Jan 10;12(1):e0170035. doi: 10.1371/journal.pone.0170035. eCollection 2017. PLoS One. 2017. PMID: 28072848 Free PMC article.
Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic.
Morélot-Panzini C, Adler D, Aguilaniu B, Allard E, Bautin N, Beaumont M, Blanc FX, Chenivesse C, Dangers L, Delclaux C, Demoule A, Devillier P, Didier A, Georges M, Housset B, Janssens JP, Laveneziana P, Laviolette L, Muir JF, Ninot G, Perez T, Peiffer C, Schmidt M, Similowski T, Straus C, Taillé C, Van Den Broecke S, Roche N; dyspnoea working group of the Société de Pneumologie de Langue Française. Morélot-Panzini C, et al. Among authors: chenivesse c. Eur Respir J. 2017 Sep 27;50(3):1701159. doi: 10.1183/13993003.01159-2017. Print 2017 Sep. Eur Respir J. 2017. PMID: 28954773 Free article. No abstract available.
121 results